Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal
Publication

Publications

Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal

Title
Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal
Type
Article in International Scientific Journal
Year
2007
Authors
palma, ac
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
araujo, f
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
duque, v
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
borges, f
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
paixao, mt
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
camacho, r
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 7
Pages: 391-398
ISSN: 1567-1348
Publisher: Elsevier
Indexing
Scientific classification
FOS: Medical and Health sciences > Health sciences
Other information
Authenticus ID: P-004-9QY
Abstract (EN): Background: Drug resistance transmission in newly diagnosed, drug-naive HIV-1 infected individuals has been previously reported, with rates ranging from 5 to 27%. The aim of this study is to investigate the prevalence of resistance-associated mutations in drug-naive, newly diagnosed patients, as well as monitoring the diversity of HIV-1 strains circulating in Portugal. Methods: One hundred eighty samples from newly diagnosed patients were prospectively collected during 2003, according to the distribution of HIV-I infections in Portugal. Epidemiological, clinical and laboratory data was collected using a standardized form. Population sequencing was performed using an automated sequencer (ABI Prism 3100, Applied Biosystems) and a commercially available assay (ViroSeq HIV-1 Genotyping System, v2.0, Abbott). Stanford HIV Sequence Database was used for interpretation of resistance data; subtyping was performed using the REGA Subtyping Tool. When subtype was unassigned, further analysis was done using an alignment with reference sequences, and phylogenetic tools like Simplot and PHYLIP. Mutations listed by the International AIDS Society-USA were considered, except E44D and V1181. Results: Patient population included 124 males (69%) and 56 females (31%), the median age being 35. Western Europe was the main region of origin (77.2%), followed by Africa (18.3%), South America (2.8%) and Asia (1.1%). The most common route of transmission was heterosexual contact (54.4%), followed by intravenous drug use (20%), homo/bisexual individuals (19.4%) and blood transfusion (0.6%). The commonest subtypes were B (41.7%) and G (29.4%), while other non-B subtypes rated 12.8% and recombinant forms represented 16.1% of the samples. Fourteen patients (7.78%) were identified as carrying resistance-associated mutations. Ten were resistant to drugs from one class, three to drugs from two classes and one to drugs from all three classes. No statistically significant associations were found between age, gender, route of transmission, subtype and resistance. Conclusions: The identification of newly diagnosed individuals carrying resistance-associated mutations confirms that drug resistance transmission is a public health problem in Portugal, with a possible impact on prevention, treatment and monitoring of HIV-1 infections. (C) 2007 Elsevier B.V. All rights reserved.
Language: English
Type (Professor's evaluation): Scientific
Contact: carolina_palma@sapo.pt
No. of pages: 8
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Tuberculosis, genetic diversity and fitness in the red deer, Cervus elaphus (2016)
Article in International Scientific Journal
Queiros, J; Vicente, J; Alves, PC; de la Fuente, J; Gortazar, C
Tracking the evolution of the G1/RHDVb recombinant strains introduced from the Iberian Peninsula to the Azores islands, Portugal (2015)
Article in International Scientific Journal
Almeida, T; Lopes, AM; Magalhaes, MJ; Neves, F; Pinheiro, A; Goncalves, D; Leitao, M; Esteves, PJ; Abrantes, J
Theileria lestoquardi displays reduced genetic diversity relative to sympatric Theileria annulata in Oman (2016)
Article in International Scientific Journal
Al Hamidhi, S; Weir, W; Kinnaird, J; Tageledin, M; beja-pereira, a; Morrison, I; Thompson, J; Tait, A; Shiels, B; Babiker, HA
The prospect of malaria elimination in the Arabian Peninsula: A population genetic approach (2014)
Article in International Scientific Journal
al-hamidhi, s; mahdy, mak; idris, ma; bin dajem, sm; al-sheikh, aah; al-qahtani, aa; al-hashami, zs; al-farsi, hm; al-mekhlafi, amq; saif-ali, r; beja-pereira, a; babiker, hae
Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia (2012)
Article in International Scientific Journal
al-farsi, hm; al-hashami, zs; bin dajem, sm; al-sheikh, aah; al-qahtani, a; beja-pereira, a; idris, ma; babiker, ha

See all (8)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-06 at 23:06:55 | Privacy Policy | Personal Data Protection Policy | Whistleblowing